Entos Pharmaceuticals Inc.
$75,000.00 CAD
≈ 12 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2024-2025
- Agreement period
- November 1, 2024 – March 31, 2025
- Reference
- nrc-cnrc:172-2024-2025-Q3-1024027
Published purpose
As part of Multinational Corporate Collaboration Program, the project “Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye” will focus on the evaluation of the safety and effectiveness of a gene, encoded in partner mRNA, in correcting an ophthalmological disease when delivered to the eye using Firm's proprietary drug delivery technology platform. The project will have two phases: (1) Formulation of proteolipid vehicle (PLV) with partner mRNA cargo followed by (2) in vitro assessment of efficacy and tolerability.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions